Clinical trial NCT00975884: Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults
Official title: Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza
Keywords: GSK Bio's influenza vaccine GSK2340272A
influenza infection
Influenza vaccine
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2009-09-14
Enrollment: 312
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.


Eligibility criteria: Inclusion Criteria:

* A male or female aged 18 years or above at the time of the first vaccination.
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
* Written informed consent obtained from the subject.
* Satisfactory baseline medical assessment by history and physical examination. Stable health status is defined as the absence of a health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within one month prior to enrolment.
* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.
* Female subjects of non-childbearing potential may be enrolled in the study.
* Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
* Female subjects of childbearing potential may be enrolled in the study, if the subject:
* has practiced adequate contraception for 30 days prior to vaccination, and
* has a negative pregnancy test on the day of vaccination, and
* has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period. Potential subjects in the follow-up phase of a prior investigational study may be enrolled if the investigator's judgment is that it will have no effect on safety, reactogenicity, or immunogenicity endpoints in this study, and that it does not violate the protocol requirements of the prior trial.
* Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
* Presence of an axillary temperature \>= 37.5ºC, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination. NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved, vaccination occurs within the window specified by the protocol, and all other eligibility criteria continue to be satisfied.
* Diagnosed with cancer, or treatment for cancer, within the past 3 years.
* Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.
* Persons with a history of histological-confirmed basal cell carcinoma of the skin successfully treated with local excision only are excepted and may enrol within 3 years of diagnosis, but other histological types of skin cancer require a 3 year untreated and disease-free window as above.
* Women who are disease-free 3 years or more after treatment for breast cancer and receiving long-term prophylactic hormonal therapy are excepted and may enrol.
* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
* Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period.
* Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period.
* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.
* An acute evolving neurological disorder or history of Guillain-Barré syndrome.
* Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
* Administration of any vaccines within 30 days before vaccination.
* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
* Pregnant or lactating female
* Female planning to become pregnant or planning to discontinue contraceptive precautions.
* Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.

Primary outcomes:
measure: Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies
timeFrame: At Day 21
measure: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
timeFrame: At Day 21
measure: Percentage of Seroconverted (SCR) Subjects for HI Antibodies
timeFrame: At Day 21
measure: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 21
Secondary outcomes:
measure: Titers for Serum HI Antibodies Against Flu A/CAL/7/2009 Strain of Influenza Disease
timeFrame: At Day 0, 21 and 42
measure: Titers for Serum HI Antibodies Against Flu A/CAL/7/2009 Strain of Influenza Disease
timeFrame: At Day 182
measure: Titers for Serum HI Antibodies Against Flu A/CAL/7/2009 Strain of Influenza Disease
timeFrame: At Day 203
measure: Titers for Serum HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 364
measure: Number of Seroconverted (SCR) Subjects for HI Antibodies
timeFrame: At Day 21 and 42
measure: Number of Seroconverted (SCR) Subjects for HI Antibodies
timeFrame: At Day 182
measure: Number of Seroconverted (SCR) Subjects for HI Antibodies
timeFrame: At Day 203
measure: Number of Seroconverted (SCR) Subjects for HI Antibodies
timeFrame: At Day 364
measure: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
timeFrame: At Days 0, 21 and 42
measure: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
timeFrame: At Day 182
measure: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
timeFrame: At Day 203
measure: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
timeFrame: At Day 364
measure: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 21 and 42
measure: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 182
measure: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 203
measure: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
timeFrame: At Day 364
measure: Titers for Serum Neutralizing Antibodies Against Flu A/Netherlands/602/09 Strain of Influenza Disease
timeFrame: At Days 0, 21 and 42
measure: Percentage of Seroconverted Subjects for Serum Neutralizing Antibodies Against Flu A/Netherlands/602/09
timeFrame: At Day 21 and 42
measure: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following first dose - Interim Analysis posted at Day 42
measure: Duration of Solicited Local Symptoms Occurring in Response to Individual Doses
timeFrame: During the 7-day (Days 0-6) post-vaccination period following first dose - Interim Analysis posted at Day 42
measure: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses - Interim Analysis posted at Day 42
measure: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
measure: Duration of Solicited Local Symptoms Occurring in Response to Individual Doses
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following first dose - Interim Analysis posted at Day 42
measure: Duration of Solicited General Symptoms Occurring in Response to Individual Doses
timeFrame: During the 7-day (Days 0-6) post-vaccination period following first dose - Interim analysis posted at Day 42
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses - Interim analysis posted at Day 42
measure: Duration of Solicited General Symptoms Occurring in Response to Individual Doses
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses - Interim analysis posed at Day 42
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
measure: Duration of Solicited General Symptoms Occurring in Response to Individual Doses
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose
measure: Number of Subjects With Adverse Events of Specific Interest (AESIs)/ Potential Immune-mediated Diseases (pIMDs)
timeFrame: From Day 0 up to Day 42 - Interim analysis posted at Day 42
measure: Number of Subjects With Adverse Events of Specific Interest (AESIs)/ Potential Immune-mediated Diseases (pIMDs)
timeFrame: From Day 0 up to Day 203 - Interim analysis posted at Day 182/203
measure: Number of Subjects With Adverse Events of Specific Interest (AESIs)/ Potential Immune-mediated Diseases (pIMDs)
timeFrame: From Day 0 up to Day 364
measure: Number of Subjects With Adverse Events of Specific Interest (AESIs)
timeFrame: From Day 0 up to Day 364
measure: Number of Subjects With Adverse Events of Specific Interest (AESIs)/ Potential Immune-mediated Diseases (pIMDs)
timeFrame: From Day 0 up to Day 546
measure: Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels
timeFrame: At Day 0 and 21 - Interim analysis posted at Day 42
measure: Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels
timeFrame: At Days 0, 21 and 42 - Interim analysis posted at Day 42
measure: Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels
timeFrame: At Days 0, 21, 42 and 182
measure: Number of Subjects With Normal/Abnormal Biochemical and Haematological Levels
timeFrame: At Day 364
measure: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
timeFrame: Within the 42-day (Days 0-41) post vaccination period - Interim analysis posted at Day 42
measure: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
timeFrame: Within 21- days post-Dose 1 vaccination (Days 0-20 in both groups) and either 63 days post-Dose 2 vaccination (Days 21-84 in D21 groups) or 21 days post-Dose 2 vaccination (Day 182-203 in M6 groups) - Interim analysis at Day 182/203
measure: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
timeFrame: Within the 21-days post-Dose 1 vaccination (Days 0-20 in both groups) and either 63 days post-Dose 2 vaccination (Days 21-84 in D21 groups) or 30 days post-Dose 2 vaccination (Days 182-212 in M6 groups)
measure: Number of Subjects With Serious Adverse Events (SAEs)
timeFrame: From Day 0 up to Day 364
measure: Number of Subjects With Serious Adverse Events (SAEs)
timeFrame: From Day 0 up to Day 546
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: GSK Investigational Site
city: Lille
country: France
facility: GSK Investigational Site
city: Paris Cedex 18
country: France
facility: GSK Investigational Site
city: Paris
country: France
facility: GSK Investigational Site
city: Poitiers
country: France
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Duval X, Caplanusi A, Laurichesse H, Deplanque D, Loulergue P, Vaman T, Launay O, Gillard P. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial. BMC Infect Dis. 2012 Jul 23;12:162. doi: 10.1186/1471-2334-12-162.